Revenue Breakdown
Composition ()
No data
Revenue Streams
InMed Pharmaceuticals Inc (INM) generates its revenue primarily from BayMedica, which accounts for 100.0% of total sales, equivalent to $1.30M. Understanding this concentration is critical for investors evaluating how INM navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, InMed Pharmaceuticals Inc maintains a gross margin of 31.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -157.45%, while the net margin is -154.17%. These profitability ratios, combined with a Return on Equity (ROE) of -82.17%, provide a clear picture of how effectively INM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, INM competes directly with industry leaders such as CUPR and LYRA. With a market capitalization of $3.08M, it holds a significant position in the sector. When comparing efficiency, INM's gross margin of 31.24% stands against CUPR's 1.67% and LYRA's 100.00%. Such benchmarking helps identify whether InMed Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
